Generative AI In Pharmaceutical Industry Market Size 2025-2029
The generative ai in pharmaceutical industry market size is forecast to increase by USD 5.4 billion, at a CAGR of 26.1% between 2024 and 2029.
The global generative ai in pharmaceutical industry market is influenced by its ability to accelerate drug discovery and development. Advanced algorithms are used for the de novo drug design of novel molecular structures, a process that curtails exploratory phases. This capability, central to artificial intelligence in drug discovery, helps in the creation and validation of new therapeutic hypotheses with greater speed. The technology is also being used in generative ai in manufacturing for process optimization. A significant trend involves the application of generative ai in life sciences to revolutionize medical and regulatory writing by automating the drafting of critical documents like clinical study reports and submission dossiers. This automation enhances efficiency across complex documentation workflows.While the market shows considerable promise, the proliferation of generative AI presents challenges related to data privacy and security. Safeguarding sensitive health information and intellectual property is a formidable task, as these advanced algorithms require access to vast and comprehensive datasets, including protected health information. The use of generative ai in healthcare necessitates robust cybersecurity measures to prevent data breaches. The imperative for secure data infrastructure and adherence to privacy regulations is a universal concern that shapes the trajectory of generative AI adoption in the pharmaceutical industry worldwide, impacting everything from research to generative ai in customer services.
What will be the Size of the Generative AI In Pharmaceutical Industry Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The global generative AI in pharmaceutical industry market is characterized by the continuous integration of advanced computational methods into the drug development lifecycle. The application of generative chemistry platforms is reshaping preclinical timelines and enhancing the precision of therapeutic hypotheses generation. Innovations in generative AI in healthcare are facilitating a deeper understanding of disease mechanisms through pathology image analysis and the creation of synthetic patient data. These ongoing developments are not isolated but are part of a broader shift towards a more data-centric approach to pharmaceutical research and development, influencing everything from target identification to clinical trial optimization.Simultaneously, the market is navigating the evolving landscape of AI model validation and regulatory frameworks. The focus on algorithmic bias mitigation and the implementation of privacy-preserving AI techniques like federated learning models are becoming integral to sustainable adoption. The use of natural language processing to analyze clinical notes is expanding, improving both pharmacovigilance and patient recruitment automation. This dynamic interplay between technological advancement and regulatory adaptation is a defining feature of the market, particularly in areas like artificial intelligence in drug discovery and generative AI in life sciences, indicating a sustained period of structured innovation.
How is this Generative AI In Pharmaceutical Industry Industry segmented?
The generative ai in pharmaceutical industry industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Method
- Text generation
- Image generation
- Audio generation
- Application
- Commercial
- Drug discovery
- Clinical development
- Research and development
- Operations
- Technology
- Deep learning models
- Natural language processing
- Generative adversarial networks
- Variational autoencoders
- Others
- Geography
- North America
- Europe
- Germany
- France
- UK
- Italy
- The Netherlands
- Spain
- APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Middle East and Africa
- South America
- Rest of World (ROW)
By Method Insights
The text generation segment is estimated to witness significant growth during the forecast period.
Text generation is a foundational method profoundly reshaping the pharmaceutical landscape by automating the creation of complex, language-based content. This technology is instrumental across the entire drug development lifecycle, from initial research to post-market surveillance. Companies are leveraging sophisticated large language models to analyze vast repositories of scientific literature, identifying novel drug targets and generating therapeutic hypotheses at a scale unattainable through manual effort. This efficiency gain is critical in an industry where time-to-market is paramount.
In clinical trials, text generation accelerates processes that have long been bottlenecks, such as the creation of clinical study reports and regulatory submission documents. Analysis indicates that generative AI could reduce regulatory submission timelines by as much as 40% through automated documentation. Advanced models are also being explored for summarizing physician-patient conversations and generating clinical notes, thereby reducing the administrative burden on healthcare professionals and researchers and allowing for a greater focus on scientific and patient-care aspects of their work.
Request Free Sample
The Text generation segment was valued at USD 376.50 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 44.1% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America stands as the preeminent market for generative AI in the pharmaceutical industry, commanding a significant share of the incremental growth at 44.1%. This leadership is due to substantial investments in healthcare technology, a robust ecosystem of pharmaceutical giants and innovative tech companies, and a supportive regulatory environment. The region is characterized by a multitude of collaborations between major technology firms and pharmaceutical leaders, who are focused on integrating AI into their core operations to enhance various stages of the value chain.
The strategic focus in North America is on the deep integration of generative AI to move beyond pilot projects to fundamental strategic imperatives. This approach is aimed at compressing drug development timelines and increasing the probability of success for new therapies. The use of AI for predictive modeling, virtual screening in drug discovery, and optimizing patient recruitment for clinical trials are key areas of activity. This proactive adoption and the presence of a vibrant innovation hub solidify the region's dominant position in the market.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global generative AI in the pharmaceutical industry is rapidly expanding, driven by its potential for improving drug discovery success rates. Companies leverage generative AI for novel drug molecules and are using AI for de novo antibody design through a sophisticated AI powered platform for molecule design. This is critical for accelerating preclinical development with AI. Core to this transformation is AI driven target identification and validation, enhanced by technologies predicting drug target interactions with AI. Additionally, synthetic data generation for rare diseases is opening new research avenues, while the industry focuses on mitigating algorithmic bias in healthcare AI and developing vocal biomarkers for diagnostics to revolutionize early detection.The market's momentum continues into later-stage development, where AI models for clinical trial protocols are essential for optimizing clinical trial patient recruitment. This efficiency aids in automating clinical study report generation and automating regulatory submission dossiers, though regulatory compliance for AI in pharma remains a key challenge. Post-approval, enhancing pharmacovigilance with NLP improves safety monitoring. The impact of generative AI in pharmaceutical manufacturing and generative AI for supply chain management is optimizing operations. Ultimately, these integrated systems support AI for personalized treatment plan creation and are key for AI for predicting therapeutic efficacy, reshaping patient outcomes.
What are the key market drivers leading to the rise in the adoption of Generative AI In Pharmaceutical Industry Industry?
- The capability to accelerate drug discovery and development is a key driver for the market.
The ability to accelerate drug discovery and development is a primary factor in the market. Conventional pharmaceutical research and development is a protracted and capital-intensive paradigm, which generative AI helps to address by automating and optimizing critical stages. Advanced algorithms analyze vast datasets of chemical and biological information to facilitate de novo drug design and generate novel molecular structures with desired therapeutic properties. This capability significantly curtails the initial, exploratory phases of drug discovery, which have historically relied on extensive trial-and-error screening. The impact is tangible, with tangible reductions in preclinical timelines being reported, as a novel drug candidate can move from discovery to preclinical candidate in a fraction of the time typically required.The escalating demand for personalized medicine is another significant dynamic. This approach aims to tailor medical treatment to the individual characteristics of each patient, departing from the traditional one-size-fits-all model. Generative AI enables this transition by analyzing multifaceted patient data at a scale and complexity that surpasses human capabilities. These sophisticated models integrate genomic data, electronic health records, and lifestyle factors to generate highly individualized treatment plans. A significant number of novel personalized therapies have been approved, underscoring the growing momentum in this field and the shift toward data-driven approaches to patient care. This comprehensive analysis allows for the prediction of a patient's likely response to a particular therapy.
What are the market trends shaping the Generative AI In Pharmaceutical Industry Industry?
- A key trend is the revolutionizing of medical and regulatory writing through automation.
A significant trend is the application of generative artificial intelligence to revolutionize medical and regulatory writing. This technology is deployed to automate the drafting of a wide array of critical documents, including clinical study reports and regulatory submission dossiers. By processing vast quantities of data from clinical trials, generative AI produces well-structured and coherent narratives with remarkable speed, accelerating timelines for approvals and communications. This shift is notable in generative ai in life sciences, where automation in medical writing is projected to reduce the effort of medical writers by up to 30%. The technology also extends to quality control, identifying inconsistencies and ensuring adherence to regulatory guidelines, making it a powerful tool for medical and regulatory professionals.Generative AI is also increasingly adopted to transform marketing and commercialization strategies, a key aspect of generative ai in customer services. This trend encompasses using AI to create highly personalized marketing content for healthcare professionals and patients and to optimize omnichannel engagement. By automating content creation, marketers can produce a high volume of tailored materials with greater efficiency. This technology helps in accelerating next-best-action omnichannel programming. As the use of generative ai in healthcare expands, the technology is also used to analyze market trends and predict patient needs, allowing companies to refine their commercial strategies proactively. This underscores a move towards more data-driven and efficient commercial models.
What challenges does the Generative AI In Pharmaceutical Industry Industry face during its growth?
- Data privacy and security imperatives present a significant challenge in an era of accelerated innovation.
The use of generative AI in the pharmaceutical industry presents a formidable challenge regarding the safeguarding of sensitive health information and intellectual property. The utility of these advanced algorithms is predicated on access to vast and comprehensive datasets, which often include protected health information and proprietary research data, making data privacy and security imperatives a central concern. The healthcare sector remains a prime target for cyberattacks, and the potential for inadvertent disclosure of sensitive information remains a paramount concern for organizations. The cross-border nature of data flows in a globalized industry further complicates compliance, with different regions having stringent and varied regulations that present a significant hurdle for multinational companies seeking to deploy generative AI solutions.The integration of generative AI into the pharmaceutical value chain is outpacing the development of clear and comprehensive regulatory frameworks, creating a significant challenge for market participants. The iterative and often opaque nature of generative AI models disrupts traditional, linear processes. Regulatory bodies globally are grappling with how to evaluate and validate the outputs of these algorithms, where the decision-making process is not easily interpretable. This is particularly critical in dominant markets that represent over 44% of the growth opportunity. The lack of established validation protocols for AI-generated data and endpoints presents a substantial hurdle for companies seeking regulatory approval for novel therapies developed using these technologies, requiring a concerted effort toward international regulatory harmonization.
Exclusive Customer Landscape
The generative ai in pharmaceutical industry market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the generative ai in pharmaceutical industry market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, generative ai in pharmaceutical industry market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AstraZeneca Plc - Offerings in this market center on providing access to advanced computational platforms that leverage generative AI for the pharmaceutical industry. These services facilitate the acceleration of drug discovery and development through strategic collaborations and internal initiatives. Key capabilities include the design and optimization of novel molecules, the identification of new therapeutic targets, and the streamlining of clinical development strategies. Companies utilize these AI-driven platforms to repurpose existing drugs by identifying new indications, predict molecular binding, and generate viable drug candidates. The core offering involves the integration of deep learning, physics-based modeling, and extensive biological datasets to enhance the precision and efficiency of bringing new therapies from conception to clinical application.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AstraZeneca Plc
- Atomwise Inc.
- Bayer AG
- BenevolentAI
- BioXcel Therapeutics Inc.
- Deep Genomics Inc.
- Exscientia plc
- Insilico Medicine
- PathAI Inc.
- Recursion Pharmaceuticals Inc.
- Relay Therapeutics Inc.
- Sanofi SA
- Schrodinger Inc.
- Shenzhen Jingtai Technology Co.Ltd
- Valo Health
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Generative Ai In Pharmaceutical Industry Market
In August 2024, Recursion Pharmaceuticals Inc. announced a definitive agreement to acquire Exscientia plc, a move intended to create a more comprehensive, end-to-end drug discovery platform by combining their respective AI-driven capabilities.In June 2024, Eli Lilly and Co. announced a collaboration with OpenAI to leverage generative AI for the discovery and development of novel antimicrobials aimed at combating drug-resistant pathogens.In May 2024, Sanofi SA revealed a first-of-its-kind collaboration with OpenAI and Formation Bio to build AI-powered software designed to accelerate multiple stages of the drug development lifecycle.In March 2024, NVIDIA Corp. announced a series of collaborations with life sciences companies, including Amgen and Recursion, to advance drug discovery and medical imaging using its BioNeMo generative AI models and healthcare microservices.In January 2024, AstraZeneca PLC and Alphabet's Isomorphic Labs announced a strategic research collaboration to apply AI to discover new medicines for complex diseases such as cancer and obesity.
Research Analyst Overview
The global generative AI in pharmaceutical industry market is fundamentally reshaping the drug development lifecycle, particularly in early-stage research. Generative AI is enabling significant drug discovery acceleration through de novo drug design and molecular structure generation, allowing for extensive chemical space exploration to uncover novel molecular structures. Processes such as target identification and hit identification are becoming more efficient, leading directly into refined lead optimization and preclinical candidate selection. Advanced models are facilitating accurate therapeutic property prediction, drug efficacy prediction, and drug toxicity prediction. This extends to sophisticated pharmacokinetic modeling and pharmacodynamic analysis, supporting the creation of small molecule therapeutics and complex biologics design, which encompasses the antibody design process and contributes to a considerable preclinical timeline reduction.Beyond discovery, generative AI is transforming clinical and operational phases, with industry expansion expectations exceeding 35% in the near term. The technology is pivotal for clinical trial optimization, utilizing synthetic patient data and synthetic control arms to enhance study design, while patient recruitment automation streamlines participant onboarding. This facilitates the creation of individualized treatment plans based on insights from biomarker discovery. The administrative burden is lessening through medical writing automation for generating clinical study reports and supporting regulatory submission drafting. In post-approval stages, pharmacovigilance enhancement improves adverse event reporting systems. Concurrently, operational efficiency is improving across the pharmaceutical supply chain with applications like predictive maintenance, and commercial strategies are adapting with more effective omnichannel marketing engagement.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Generative AI In Pharmaceutical Industry Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
308
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 26.1%
|
|
Market growth 2024-2029
|
USD 5.4 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
24.6%
|
|
Key countries
|
US, Canada, Mexico, Germany, France, UK, Italy, The Netherlands, Spain, China, India, Japan, South Korea, Australia, Indonesia, Saudi Arabia, UAE, South Africa, Israel, Turkey, Brazil, Argentina, Colombia
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Generative AI In Pharmaceutical Industry Market Research and Growth Report?
- CAGR of the Generative AI In Pharmaceutical Industry industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, APAC, Middle East and Africa, South America
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the generative ai in pharmaceutical industry market growth of industry companies
We can help! Our analysts can customize this generative ai in pharmaceutical industry market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Method
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Generative AI In Pharmaceutical Industry Market 2019 - 2023
- Historic Market Size - Data Table on Global Generative AI In Pharmaceutical Industry Market 2019 - 2023 ($ billion)
- 5.2 Method segment analysis 2019 - 2023
- Historic Market Size - Method Segment 2019 - 2023 ($ billion)
- 5.3 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.4 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Five Forces Analysis
- 6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
7 Market Segmentation by Method
- 7 Market Segmentation by Method
- 7.1 Market segments
- Chart on Method - Market share 2024-2029 (%)
- Data Table on Method - Market share 2024-2029 (%)
- 7.2 Comparison by Method
- Chart on Comparison by Method
- Data Table on Comparison by Method
- 7.3 Text generation - Market size and forecast 2024-2029
- Chart on Text generation - Market size and forecast 2024-2029 ($ billion)
- Data Table on Text generation - Market size and forecast 2024-2029 ($ billion)
- Chart on Text generation - Year-over-year growth 2024-2029 (%)
- Data Table on Text generation - Year-over-year growth 2024-2029 (%)
- 7.4 Image generation - Market size and forecast 2024-2029
- Chart on Image generation - Market size and forecast 2024-2029 ($ billion)
- Data Table on Image generation - Market size and forecast 2024-2029 ($ billion)
- Chart on Image generation - Year-over-year growth 2024-2029 (%)
- Data Table on Image generation - Year-over-year growth 2024-2029 (%)
- 7.5 Audio generation - Market size and forecast 2024-2029
- Chart on Audio generation - Market size and forecast 2024-2029 ($ billion)
- Data Table on Audio generation - Market size and forecast 2024-2029 ($ billion)
- Chart on Audio generation - Year-over-year growth 2024-2029 (%)
- Data Table on Audio generation - Year-over-year growth 2024-2029 (%)
- 7.6 Market opportunity by Method
- Market opportunity by Method ($ billion)
- Data Table on Market opportunity by Method ($ billion)
8 Market Segmentation by Application
- 8 Market Segmentation by Application
- 8.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 8.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 8.3 Commercial - Market size and forecast 2024-2029
- Chart on Commercial - Market size and forecast 2024-2029 ($ billion)
- Data Table on Commercial - Market size and forecast 2024-2029 ($ billion)
- Chart on Commercial - Year-over-year growth 2024-2029 (%)
- Data Table on Commercial - Year-over-year growth 2024-2029 (%)
- 8.4 Drug discovery - Market size and forecast 2024-2029
- Chart on Drug discovery - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug discovery - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug discovery - Year-over-year growth 2024-2029 (%)
- Data Table on Drug discovery - Year-over-year growth 2024-2029 (%)
- 8.5 Clinical development - Market size and forecast 2024-2029
- Chart on Clinical development - Market size and forecast 2024-2029 ($ billion)
- Data Table on Clinical development - Market size and forecast 2024-2029 ($ billion)
- Chart on Clinical development - Year-over-year growth 2024-2029 (%)
- Data Table on Clinical development - Year-over-year growth 2024-2029 (%)
- 8.6 Research and development - Market size and forecast 2024-2029
- Chart on Research and development - Market size and forecast 2024-2029 ($ billion)
- Data Table on Research and development - Market size and forecast 2024-2029 ($ billion)
- Chart on Research and development - Year-over-year growth 2024-2029 (%)
- Data Table on Research and development - Year-over-year growth 2024-2029 (%)
- 8.7 Operations - Market size and forecast 2024-2029
- Chart on Operations - Market size and forecast 2024-2029 ($ billion)
- Data Table on Operations - Market size and forecast 2024-2029 ($ billion)
- Chart on Operations - Year-over-year growth 2024-2029 (%)
- Data Table on Operations - Year-over-year growth 2024-2029 (%)
- 8.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
9 Market Segmentation by Technology
- 9 Market Segmentation by Technology
- 9.1 Market segments
- Chart on Technology - Market share 2024-2029 (%)
- Data Table on Technology - Market share 2024-2029 (%)
- 9.2 Comparison by Technology
- Chart on Comparison by Technology
- Data Table on Comparison by Technology
- 9.3 Deep learning models - Market size and forecast 2024-2029
- Chart on Deep learning models - Market size and forecast 2024-2029 ($ billion)
- Data Table on Deep learning models - Market size and forecast 2024-2029 ($ billion)
- Chart on Deep learning models - Year-over-year growth 2024-2029 (%)
- Data Table on Deep learning models - Year-over-year growth 2024-2029 (%)
- 9.4 Natural language processing - Market size and forecast 2024-2029
- Chart on Natural language processing - Market size and forecast 2024-2029 ($ billion)
- Data Table on Natural language processing - Market size and forecast 2024-2029 ($ billion)
- Chart on Natural language processing - Year-over-year growth 2024-2029 (%)
- Data Table on Natural language processing - Year-over-year growth 2024-2029 (%)
- 9.5 Generative adversarial networks - Market size and forecast 2024-2029
- Chart on Generative adversarial networks - Market size and forecast 2024-2029 ($ billion)
- Data Table on Generative adversarial networks - Market size and forecast 2024-2029 ($ billion)
- Chart on Generative adversarial networks - Year-over-year growth 2024-2029 (%)
- Data Table on Generative adversarial networks - Year-over-year growth 2024-2029 (%)
- 9.6 Variational autoencoders - Market size and forecast 2024-2029
- Chart on Variational autoencoders - Market size and forecast 2024-2029 ($ billion)
- Data Table on Variational autoencoders - Market size and forecast 2024-2029 ($ billion)
- Chart on Variational autoencoders - Year-over-year growth 2024-2029 (%)
- Data Table on Variational autoencoders - Year-over-year growth 2024-2029 (%)
- 9.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.8 Market opportunity by Technology
- Market opportunity by Technology ($ billion)
- Data Table on Market opportunity by Technology ($ billion)
10 Customer Landscape
- 10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 11.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 11.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 11.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 11.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 11.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 11.4.2 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 11.4.3 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 11.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 11.4.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 11.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 11.5 APAC - Market size and forecast 2024-2029
- Chart on APAC - Market size and forecast 2024-2029 ($ billion)
- Data Table on APAC - Market size and forecast 2024-2029 ($ billion)
- Chart on APAC - Year-over-year growth 2024-2029 (%)
- Data Table on APAC - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - APAC
- Data Table on Regional Comparison - APAC
- 11.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 11.5.2 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 11.5.3 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 11.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 11.5.5 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 11.5.6 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 11.6 Middle East and Africa - Market size and forecast 2024-2029
- Chart on Middle East and Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on Middle East and Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on Middle East and Africa - Year-over-year growth 2024-2029 (%)
- Data Table on Middle East and Africa - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Middle East and Africa
- Data Table on Regional Comparison - Middle East and Africa
- 11.6.1 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 11.6.2 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 11.6.3 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 11.6.4 Israel - Market size and forecast 2024-2029
- Chart on Israel - Market size and forecast 2024-2029 ($ billion)
- Data Table on Israel - Market size and forecast 2024-2029 ($ billion)
- Chart on Israel - Year-over-year growth 2024-2029 (%)
- Data Table on Israel - Year-over-year growth 2024-2029 (%)
- 11.6.5 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 11.7 South America - Market size and forecast 2024-2029
- Chart on South America - Market size and forecast 2024-2029 ($ billion)
- Data Table on South America - Market size and forecast 2024-2029 ($ billion)
- Chart on South America - Year-over-year growth 2024-2029 (%)
- Data Table on South America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - South America
- Data Table on Regional Comparison - South America
- 11.7.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 11.7.2 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ billion)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ billion)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 11.7.3 Colombia - Market size and forecast 2024-2029
- Chart on Colombia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Colombia - Market size and forecast 2024-2029 ($ billion)
- Chart on Colombia - Year-over-year growth 2024-2029 (%)
- Data Table on Colombia - Year-over-year growth 2024-2029 (%)
- 11.8 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
12 Drivers, Challenges, and Opportunity
- 12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Accelerating drug discovery and development
- Enhancing personalized medicine and treatment
- Optimizing clinical trials
- 12.2 Market challenges
- Data privacy and security imperatives in era of accelerated innovation
- Navigating evolving regulatory and compliance gauntlet
- Confronting ethical dilemmas and algorithmic bias
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Revolutionizing medical and regulatory writing
- Transforming pharmaceutical marketing and commercialization
- Enhancing pharmaceutical manufacturing and supply chain management
13 Competitive Landscape
- 13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14 Competitive Analysis
- 14.1 Companies profiled
- 14.2 Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 14.5 Atomwise Inc.
- Atomwise Inc. - Overview
- Atomwise Inc. - Product / Service
- Atomwise Inc. - Key offerings
- SWOT
- 14.6 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 14.7 BenevolentAI
- BenevolentAI - Overview
- BenevolentAI - Product / Service
- BenevolentAI - Key offerings
- SWOT
- 14.8 BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. - Overview
- BioXcel Therapeutics Inc. - Product / Service
- BioXcel Therapeutics Inc. - Key offerings
- SWOT
- 14.9 Deep Genomics Inc.
- Deep Genomics Inc. - Overview
- Deep Genomics Inc. - Product / Service
- Deep Genomics Inc. - Key offerings
- SWOT
- 14.10 Exscientia plc
- Exscientia plc - Overview
- Exscientia plc - Product / Service
- Exscientia plc - Key offerings
- SWOT
- 14.11 Insilico Medicine
- Insilico Medicine - Overview
- Insilico Medicine - Product / Service
- Insilico Medicine - Key offerings
- SWOT
- 14.12 PathAI Inc.
- PathAI Inc. - Overview
- PathAI Inc. - Product / Service
- PathAI Inc. - Key offerings
- SWOT
- 14.13 Recursion Pharmaceuticals Inc.
- Recursion Pharmaceuticals Inc. - Overview
- Recursion Pharmaceuticals Inc. - Product / Service
- Recursion Pharmaceuticals Inc. - Key offerings
- SWOT
- 14.14 Relay Therapeutics Inc.
- Relay Therapeutics Inc. - Overview
- Relay Therapeutics Inc. - Product / Service
- Relay Therapeutics Inc. - Key offerings
- SWOT
- 14.15 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 14.16 Schrodinger Inc.
- Schrodinger Inc. - Overview
- Schrodinger Inc. - Business segments
- Schrodinger Inc. - Key offerings
- Schrodinger Inc. - Segment focus
- SWOT
- 14.17 Shenzhen Jingtai Technology Co.Ltd
- Shenzhen Jingtai Technology Co.Ltd - Overview
- Shenzhen Jingtai Technology Co.Ltd - Product / Service
- Shenzhen Jingtai Technology Co.Ltd - Key offerings
- SWOT
- 14.18 Valo Health
- Valo Health - Overview
- Valo Health - Product / Service
- Valo Health - Key offerings
- SWOT
15 Appendix
- 15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.5 Data procurement
- 15.6 Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
